Roskamp Institute Release: Key Clinical Trial of Alzheimer’s Disease Drug Begins in Europe

Published: Feb 14, 2012

SARASOTA, Fla.--(BUSINESS WIRE)--A research team today announced the launch of a European large-scale clinical trial of Nilvadipine, an Alzheimer’s disease drug developed at the Roskamp Institute ( in Sarasota. More than 500 Alzheimer’s patients in nine European countries will participate in the phase III trial designed to study the effectiveness of the medication.

Back to news